These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 37871711)

  • 41. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction: an analysis of the PARAMOUNT trial.
    Jhund PS; Claggett B; Packer M; Zile MR; Voors AA; Pieske B; Lefkowitz M; Shi V; Bransford T; McMurray JJ; Solomon SD
    Eur J Heart Fail; 2014 Jun; 16(6):671-7. PubMed ID: 24692284
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Sacubitril-valsartan as a treatment for apparent resistant hypertension in patients with heart failure and preserved ejection fraction.
    Jackson AM; Jhund PS; Anand IS; Düngen HD; Lam CSP; Lefkowitz MP; Linssen G; Lund LH; Maggioni AP; Pfeffer MA; Rouleau JL; Saraiva JFK; Senni M; Vardeny O; Wijkman MO; Yilmaz MB; Saito Y; Zile MR; Solomon SD; McMurray JJV
    Eur Heart J; 2021 Sep; 42(36):3741-3752. PubMed ID: 34392331
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effect of Angiotensin-Neprilysin Versus Renin-Angiotensin System Inhibition on Renal Outcomes: A Systematic Review and Meta-Analysis.
    Xu Y; Chen Y; Zhao JW; Li C; Wang AY
    Front Pharmacol; 2021; 12():604017. PubMed ID: 34867310
    [No Abstract]   [Full Text] [Related]  

  • 44. Sacubitril/Valsartan Across the Spectrum of Ejection Fraction in Heart Failure.
    Solomon SD; Vaduganathan M; L Claggett B; Packer M; Zile M; Swedberg K; Rouleau J; A Pfeffer M; Desai A; Lund LH; Kober L; Anand I; Sweitzer N; Linssen G; Merkely B; Luis Arango J; Vinereanu D; Chen CH; Senni M; Sibulo A; Boytsov S; Shi V; Rizkala A; Lefkowitz M; McMurray JJV
    Circulation; 2020 Feb; 141(5):352-361. PubMed ID: 31736342
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of Angiotensin Receptor-Neprilysin Inhibitors Versus Enalapril or Valsartan on Patients With Heart Failure: A Systematic Review and Meta-Analysis.
    Jain A; Meyur S; Wadhwa L; Singh K; Sharma R; Panchal I; Varrassi G
    Cureus; 2023 Jul; 15(7):e41566. PubMed ID: 37554618
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Angiotensin-neprilysin inhibition and renal outcomes across the spectrum of ejection fraction in heart failure.
    Mc Causland FR; Lefkowitz MP; Claggett B; Packer M; Senni M; Gori M; Jhund PS; McGrath MM; Rouleau JL; Shi V; Swedberg K; Vaduganathan M; Zannad F; Pfeffer MA; Zile M; McMurray JJV; Solomon SD
    Eur J Heart Fail; 2022 Sep; 24(9):1591-1598. PubMed ID: 34989105
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Variation in Renal Function Following Transition to Sacubitril/Valsartan in Patients With Heart Failure.
    Chatur S; Claggett BL; McCausland FR; Rouleau J; Zile MR; Packer M; Pfeffer MA; Lefkowitz M; McMurray JJV; Solomon SD; Vaduganathan M
    J Am Coll Cardiol; 2023 Apr; 81(15):1443-1455. PubMed ID: 36812948
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A putative placebo analysis of the effects of sacubitril/valsartan in heart failure across the full range of ejection fraction.
    Vaduganathan M; Jhund PS; Claggett BL; Packer M; Widimský J; Seferovic P; Rizkala A; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
    Eur Heart J; 2020 Jul; 41(25):2356-2362. PubMed ID: 32221596
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure).
    Vardeny O; Claggett B; Kachadourian J; Pearson SM; Desai AS; Packer M; Rouleau J; Zile MR; Swedberg K; Lefkowitz M; Shi V; McMurray JJV; Solomon SD
    Circ Heart Fail; 2018 Apr; 11(4):e004745. PubMed ID: 29643067
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Baseline Characteristics of Patients With Heart Failure and Preserved Ejection Fraction in the PARAGON-HF Trial.
    Solomon SD; Rizkala AR; Lefkowitz MP; Shi VC; Gong J; Anavekar N; Anker SD; Arango JL; Arenas JL; Atar D; Ben-Gal T; Boytsov SA; Chen CH; Chopra VK; Cleland J; Comin-Colet J; Duengen HD; Echeverría Correa LE; Filippatos G; Flammer AJ; Galinier M; Godoy A; Goncalvesova E; Janssens S; Katova T; Køber L; Lelonek M; Linssen G; Lund LH; O'Meara E; Merkely B; Milicic D; Oh BH; Perrone SV; Ranjith N; Saito Y; Saraiva JF; Shah S; Seferovic PM; Senni M; Sibulo AS; Sim D; Sweitzer NK; Taurio J; Vinereanu D; Vrtovec B; Widimský J; Yilmaz MB; Zhou J; Zweiker R; Anand IS; Ge J; Lam CSP; Maggioni AP; Martinez F; Packer M; Pfeffer MA; Pieske B; Redfield MM; Rouleau JL; Van Veldhuisen DJ; Zannad F; Zile MR; McMurray JJV
    Circ Heart Fail; 2018 Jul; 11(7):e004962. PubMed ID: 29980595
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sacubitril/valsartan: An important piece in the therapeutic puzzle of heart failure.
    Marques da Silva P; Aguiar C
    Rev Port Cardiol; 2017 Sep; 36(9):655-668. PubMed ID: 28844335
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Initial clinical experience with the first drug (sacubitril/valsartan) in a new class - angiotensin receptor neprilysin inhibitors in patients with heart failure with reduced left ventricular ejection fraction in Poland.
    Kałużna-Oleksy M; Kolasa J; Migaj J; Pawlak A; Lelonek M; Nessler J; Straburzyńska-Migaj E
    Kardiol Pol; 2018; 76(2):381-387. PubMed ID: 29192956
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Comparative Effectiveness of Sacubitril-Valsartan Versus ACE/ARB Therapy in Heart Failure With Reduced Ejection Fraction.
    Tan NY; Sangaralingham LR; Sangaralingham SJ; Yao X; Shah ND; Dunlay SM
    JACC Heart Fail; 2020 Jan; 8(1):43-54. PubMed ID: 31838035
    [TBL] [Abstract][Full Text] [Related]  

  • 54. NT-proBNP Response to Sacubitril/Valsartan in Hospitalized Heart Failure Patients With Reduced Ejection Fraction: TRANSITION Study.
    Pascual-Figal D; Wachter R; Senni M; Bao W; Noè A; Schwende H; Butylin D; Prescott MF;
    JACC Heart Fail; 2020 Oct; 8(10):822-833. PubMed ID: 32800508
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Sacubitril/Valsartan (LCZ696) in Heart Failure.
    Khder Y; Shi V; McMurray JJV; Lefkowitz MP
    Handb Exp Pharmacol; 2017; 243():133-165. PubMed ID: 28004291
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The role of sacubitril/valsartan in the treatment of chronic heart failure with reduced ejection fraction in hypertensive patients with comorbidities: From clinical trials to real-world settings.
    Mazza A; Townsend DM; Torin G; Schiavon L; Camerotto A; Rigatelli G; Cuppini S; Minuz P; Rubello D
    Biomed Pharmacother; 2020 Oct; 130():110596. PubMed ID: 34321170
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Difference between Sacubitril Valsartan and Valsartan on Vascular Endothelial Function, APN, MMP-9, and BNP Levels in Patients with Hypertension and Chronic Heart Failure.
    Du H; Li X; Zhao W; Jiang N
    J Healthc Eng; 2022; 2022():9494981. PubMed ID: 35222898
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension.
    Codina P; Domingo M; Barceló E; Gastelurrutia P; Casquete D; Vila J; Abdul-Jawad Altisent O; Spitaleri G; Cediel G; Santiago-Vacas E; Zamora E; Ruiz-Cueto M; Santesmases J; de la Espriella R; Pascual-Figal DA; Nuñez J; Lupón J; Bayes-Genis A
    ESC Heart Fail; 2022 Aug; 9(4):2170-2180. PubMed ID: 35588235
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [ANMCO position paper on sacubitril/valsartan in the management of patients with heart failure].
    Di Tano G; Di Lenarda A; Gabrielli D; Aspromonte N; De Maria R; Frigerio M; Iacoviello M; Mortara A; Murrone A; Nardi F; Oliva F; Pontremoli R; Scherillo M; Senni M; Urbinati S; Gulizia MM
    G Ital Cardiol (Rome); 2018 Oct; 19(10):568-590. PubMed ID: 30281045
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Insights into implementation of sacubitril/valsartan into clinical practice.
    Martens P; Beliën H; Dupont M; Mullens W
    ESC Heart Fail; 2018 Jun; 5(3):275-283. PubMed ID: 29464879
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.